C Kent Osborne

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11571190/publications.pdf

Version: 2024-02-01

184 papers	38,312 citations	4960 84 h-index	5255 165 g-index
185 all docs	185 docs citations	185 times ranked	29472 citing authors

#	Article	IF	Citations
1	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology, 2013, 24, 2206-2223.	1.2	2,805
2	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Journal of Clinical Oncology, 2010, 28, 2784-2795.	1.6	2,667
3	Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer. Journal of Clinical Oncology, 1999, 17, 1474-1474.	1.6	1,880
4	Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy. Journal of the National Cancer Institute, 2008, 100, 672-679.	6.3	1,632
5	Tailoring therapiesâ€"improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals of Oncology, 2015, 26, 1533-1546.	1.2	1,449
6	Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncology, The, 2010, 11, 55-65.	10.7	1,252
7	Tamoxifen in the Treatment of Breast Cancer. New England Journal of Medicine, 1998, 339, 1609-1618.	27.0	1,156
8	Mechanisms of Tamoxifen Resistance: Increased Estrogen Receptor-HER2/neu Cross-Talk in ER/HER2-Positive Breast Cancer. Journal of the National Cancer Institute, 2004, 96, 926-935.	6.3	1,048
9	Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer. Clinical Cancer Research, 2015, 21, 1688-1698.	7.0	990
10	Mechanisms of Endocrine Resistance in Breast Cancer. Annual Review of Medicine, 2011, 62, 233-247.	12.2	963
11	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Unabridged Version). Archives of Pathology and Laboratory Medicine, 2010, 134, e48-e72.	2.5	855
12	Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet, The, 2003, 362, 362-369.	13.7	804
13	Role of the Estrogen Receptor Coactivator AIB1 (SRC-3) and HER-2/neu in Tamoxifen Resistance in Breast Cancer. Journal of the National Cancer Institute, 2003, 95, 353-361.	6.3	717
14	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Archives of Pathology and Laboratory Medicine, 2010, 134, 907-922.	2.5	697
15	Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Research and Treatment, 1992, 24, 85-95.	2.5	670
16	Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases. Journal of Clinical Oncology, 2003, 21, 1973-1979.	1.6	636
17	The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer, 1980, 46, 2884-2888.	4.1	629
18	Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance. Endocrine Reviews, 2008, 29, 217-233.	20.1	470

#	Article	IF	Citations
19	Molecular Changes in Tamoxifen-Resistant Breast Cancer: Relationship Between Estrogen Receptor, HER-2, and p38 Mitogen-Activated Protein Kinase. Journal of Clinical Oncology, 2005, 23, 2469-2476.	1.6	436
20	Biology of Progesterone Receptor Loss in Breast Cancer and Its Implications for Endocrine Therapy. Journal of Clinical Oncology, 2005, 23, 7721-7735.	1.6	430
21	The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer, 1980, 46, 2884-2888.	4.1	427
22	Estrogen Receptorâ€"Positive, Progesterone Receptorâ€"Negative Breast Cancer: Association With Growth Factor Receptor Expression and Tamoxifen Resistance. Journal of the National Cancer Institute, 2005, 97, 1254-1261.	6.3	423
23	Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function. Cancer Research, 2008, 68, 826-833.	0.9	415
24	Steroid hormone receptors in breast cancer management. Breast Cancer Research and Treatment, 1998, 51, 227-238.	2.5	401
25	Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance. Clinical Cancer Research, 2004, 10, 331s-336s.	7.0	397
26	Comparison of Fulvestrant Versus Tamoxifen for the Treatment of Advanced Breast Cancer in Postmenopausal Women Previously Untreated With Endocrine Therapy: A Multinational, Double-Blind, Randomized Trial. Journal of Clinical Oncology, 2004, 22, 1605-1613.	1.6	392
27	ICI 182,780 (Faslodex?). Cancer, 2000, 89, 817-825.	4.1	365
28	Selective Estrogen Receptor Modulators: Structure, Function, and Clinical Use. Journal of Clinical Oncology, 2000, 18, 3172-3186.	1.6	317
29	The Osteogenic Niche Promotes Early-Stage Bone Colonization of Disseminated Breast Cancer Cells. Cancer Cell, 2015, 27, 193-210.	16.8	308
30	Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women. Cancer, 2003, 98, 229-238.	4.1	305
31	Estrogen-Receptor Biology: Continuing Progress and Therapeutic Implications. Journal of Clinical Oncology, 2005, 23, 1616-1622.	1.6	301
32	Enhancement of Insulin-Like Growth Factor Signaling in Human Breast Cancer: Estrogen Regulation of Insulin Receptor Substrate-1 Expression in Vitro and in Vivo. Molecular Endocrinology, 1999, 13, 787-796.	3.7	292
33	Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clinical Cancer Research, 2005, 11, 865s-70s.	7.0	277
34	Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study. , 2000, 89, 111-117.		271
35	Tumor Characteristics and Clinical Outcome of Tubular and Mucinous Breast Carcinomas. Journal of Clinical Oncology, 1999, 17, 1442-1442.	1.6	259
36	Significance of Axillary Lymph Node Metastasis in Primary Breast Cancer. Journal of Clinical Oncology, 1999, 17, 2334-2334.	1.6	258

#	Article	IF	Citations
37	Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase. Cell, 2011, 144, 703-718.	28.9	246
38	Insulin-Like Growth Factor-ll (IGF-II): A Potential Autocrine/Paracrine Growth Factor for Human Breast Cancer Acting via the IGF-I Receptor. Molecular Endocrinology, 1989, 3, 1701-1709.	3.7	240
39	Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2â€"Overexpressing Breast Cancer: TBCRC 006. Journal of Clinical Oncology, 2013, 31, 1726-1731.	1.6	238
40	Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet, The, 2009, 374, 2055-2063.	13.7	237
41	Neoadjuvant Trastuzumab Induces Apoptosis in Primary Breast Cancers. Journal of Clinical Oncology, 2005, 23, 2460-2468.	1.6	235
42	Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2â€"Overexpressing Locally Advanced Breast Cancers. Journal of Clinical Oncology, 2011, 29, 166-173.	1.6	235
43	The <i>HOXB13:IL17BR</i> Expression Index Is a Prognostic Factor in Early-Stage Breast Cancer. Journal of Clinical Oncology, 2006, 24, 4611-4619.	1.6	232
44	Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Research and Treatment, 1987, 9, 111-121.	2.5	229
45	HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer. Clinical Cancer Research, 2004, 10, 5670-5676.	7.0	223
46	Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers - role of estrogen receptor and HER2 reactivation. Breast Cancer Research, 2011, 13, R121.	5.0	219
47	Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Research and Treatment, 1998, 52, 227-237.	2.5	213
48	Targeting HER2 for the Treatment of Breast Cancer. Annual Review of Medicine, 2015, 66, 111-128.	12.2	213
49	Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Research, 2010, 12, R40.	5.0	211
50	An international study to increase concordance in Ki67 scoring. Modern Pathology, 2015, 28, 778-786.	5.5	195
51	Patterns of Resistance and Incomplete Response to Docetaxel by Gene Expression Profiling in Breast Cancer Patients. Journal of Clinical Oncology, 2005, 23, 1169-1177.	1.6	189
52	Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer, 2010, 116, 1234-1242.	4.1	181
53	Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Research and Treatment, 1993, 26, 237-246.	2.5	180
54	Low Levels of Estrogen Receptor Î² Protein Predict Resistance to Tamoxifen Therapy in Breast Cancer. Clinical Cancer Research, 2004, 10, 7490-7499.	7.0	178

#	Article	IF	Citations
55	Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent HER-Targeted Therapy. Journal of the National Cancer Institute, 2007, 99, 694-705.	6.3	176
56	Oxidative Stress and AP-1 Activity in Tamoxifen-Resistant Breast Tumors In Vivo. Journal of the National Cancer Institute, 2000, 92, 1926-1934.	6.3	170
57	Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemotherapy and Pharmacology, 2005, 56, 10-20.	2.3	170
58	Towards personalized treatment for early stage HER2-positive breast cancer. Nature Reviews Clinical Oncology, 2020, 17, 233-250.	27.6	166
59	Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 596.	7.4	163
60	Human breast cancer in the athymic nude mouse: Cystostatic effects of long-term antiestrogen therapy. European Journal of Cancer & Clinical Oncology, 1987, 23, 1189-1196.	0.7	162
61	Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptorâ€“Positive Metastatic Breast Cancer: A Randomized Phase II Study. Clinical Cancer Research, 2011, 17, 1147-1159.	7.0	158
62	An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Research, 2014, 24, 809-819.	12.0	155
63	Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma. Cancer, 2005, 104, 236-239.	4.1	154
64	First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2â€“Positive and Hormone Receptorâ€“Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. Journal of Clinical Oncology, 2018, 36, 2826-2835.	1.6	152
65	Mechanisms of Tumor Regression and Resistance to Estrogen Deprivation and Fulvestrant in a Model of Estrogen Receptorâ€“Positive, HER-2/<i>neu</i>-Positive Breast Cancer. Cancer Research, 2006, 66, 8266-8273.	0.9	147
66	An autopsy study of histologic progression in non-Hodgkin's lymphomas 192 cases from the national cancer institute. Cancer, 1983, 52, 393-398.	4.1	146
67	Forkhead Homologue in Rhabdomyosarcoma Functions as a Bifunctional Nuclear Receptor-interacting Protein with Both Coactivator and Corepressor Functions. Journal of Biological Chemistry, 2001, 276, 27907-27912.	3.4	144
68	Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptorâ€“Positive Early Breast Cancer: PALLET Trial. Journal of Clinical Oncology, 2019, 37, 178-189.	1.6	136
69	Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast, 2003, 12, 362-367.	2.2	129
70	The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemotherapy and Pharmacology, 1994, 34, 89-95.	2.3	126
71	Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Research and Treatment, 2008, 108, 233-240.	2.5	123
72	Development of Resistance to Targeted Therapies Transforms the Clinically Associated Molecular Profile Subtype of Breast Tumor Xenografts. Cancer Research, 2008, 68, 7493-7501.	0.9	120

#	Article	IF	Citations
73	bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer, 1998, 82, 1296-1302.	4.1	119
74	FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6600-E6609.	7.1	119
75	Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene, 2002, 21, 7680-7689.	5.9	113
76	Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil Versus Cyclophosphamide, Doxorubicin, and Fluorouracil With and Without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Intergroup Protocol INT-0102. Journal of Clinical Oncology, 2005, 23, 8313-8321.	1.6	113
77	Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Research, 2003, 63, 2434-9.	0.9	113
78	Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. Npj Breast Cancer, 2016, 2, 16014.	5.2	109
79	FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26823-26834.	7.1	103
80	The changing role of ER in endocrine resistance. Breast, 2015, 24, S60-S66.	2.2	97
81	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. Journal of the National Cancer Institute, 2020, 112, 46-54.	6.3	97
82	Correlation of primary breast cancer histopathology and estrogen receptor content. Breast Cancer Research and Treatment, 1981, 1, 37-41.	2.5	96
83	Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Research and Treatment, 2009, 114, 287-299.	2.5	94
84	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews, 2020, 84, 101965.	7.7	92
85	Endocrine responsiveness: Understanding how progesterone receptor can be used to select endocrine therapy. Breast, 2005, 14, 458-465.	2.2	91
86	Tamoxifen-Bound Estrogen Receptor (ER) Strongly Interacts with the Nuclear Matrix Protein HET/SAF-B, a Novel Inhibitor of ER-Mediated Transactivation. Molecular Endocrinology, 2000, 14, 369-381.	3.7	89
87	Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance. Breast Cancer Research and Treatment, 2006, 95, 229-233.	2.5	88
88	The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Research and Treatment, 2006, 98, 315-327.	2.5	88
89	HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clinical Cancer Research, 2017, 23, 5123-5134.	7.0	85
90	Biological mechanisms and clinical implications of endocrine resistance in breast cancer. Breast, 2011, 20, S42-S49.	2.2	82

#	Article	IF	Citations
91	Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. Clinical Cancer Research, 2015, 21, 3995-4003.	7.0	82
92	Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. Npj Breast Cancer, 2018, 4, 38.	5.2	78
93	Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer. Breast, 2013, 22, S12-S18.	2.2	77
94	Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival. Cancer Research, 2016, 76, 1942-1953.	0.9	77
95	Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER2/neu-Overexpressing Breast Tumor Xenografts. Clinical Cancer Research, 2011, 17, 1351-1361.	7.0	76
96	In Vitro Model Systems for the Study of Hormone-Dependent Human Breast Cancer. New England Journal of Medicine, 1977, 296, 154-159.	27.0	75
97	Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. Histopathology, 2019, 75, 225-235.	2.9	74
98	Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Research and Treatment, 2018, 167, 731-740.	2.5	71
99	Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell, 2006, 10, 487-499.	16.8	68
100	Endocrinology and hormone therapy in breast cancer: New insight into estrogen receptor-Î± function and its implication for endocrine therapy resistance in breast cancer. Breast Cancer Research, 2005, 7, 205-11.	5.0	62
101	Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Research, 2014, 16, 430.	5.0	61
102	Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. JAMA Oncology, 2020, 6, 505.	7.1	51
103	Gene Polymorphisms in Cyclophosphamide Metabolism Pathway,Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer. Clinical Cancer Research, 2010, 16, 6169-6176.	7.0	50
104	Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Research and Treatment, 2006, 95, 7-12.	2.5	49
105	Scaffold Attachment Factor SAFB1 Suppresses Estrogen Receptor Î±-Mediated Transcription in Part via Interaction with Nuclear Receptor Corepressor. Molecular Endocrinology, 2006, 20, 311-320.	3.7	49
106	Therapeutic potential of the dual EGFR/HER2Âinhibitor AZD8931 in circumventing endocrine resistance. Breast Cancer Research and Treatment, 2014, 144, 263-272.	2.5	49
107	Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clinical Cancer Research, 2021, 27, 4870-4882.	7.0	49
108	Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Research and Treatment, 1997, 43, 153-163.	2.5	48

#	Article	IF	Citations
109	Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Research, 2015, 17, 3.	5.0	48
110	The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. British Journal of Cancer, 2019, 120, 331-339.	6.4	48
111	Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. Nature Medicine, 2018, 24, 505-511.	30.7	47
112	Nitric Oxide Synthase Variants and Disease-Free Survival among Treated and Untreated Breast Cancer Patients in a Southwest Oncology Group Clinical Trial. Clinical Cancer Research, 2009, 15, 5258-5266.	7.0	46
113	De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. Breast, 2017, 34, S19-S26.	2.2	46
114	Enhanced Gene Expression in Breast Cancer Cells in Vitro and Tumors in Vivo. Molecular Therapy, 2002, 6, 783-792.	8.2	43
115	Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer. Molecular Cancer Research, 2019, 17, 2318-2330.	3.4	41
116	A Neoadjuvant, Randomized, Open-Label Phase II Trial of Afatinib Versus Trastuzumab Versus Lapatinib in Patients With Locally Advanced HER2-Positive Breast Cancer. Clinical Breast Cancer, 2015, 15, 101-109.	2.4	40
117	TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clinical Cancer Research, 2020, 26, 821-827.	7.0	40
118	Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Molecular Cancer Research, 2016, 14, 470-481.	3.4	39
119	Prognostic factors: Rationale and methods of analysis and integration. Breast Cancer Research and Treatment, 1994, 32, 105-112.	2.5	38
120	A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer. Journal of Clinical Medicine, 2019, 8, 1772.	2.4	36
121	Optimizing Chemotherapy-Free Survival for the ER/HER2-Positive Metastatic Breast Cancer Patient. Clinical Cancer Research, 2011, 17, 5559-5561.	7.0	33
122	Hormone receptors in primary and advanced breast cancer. Clinics in Endocrinology and Metabolism, 1980, 9, 361-368.	1.6	32
123	Low SAFB levels are associated with worse outcome in breast cancer patients. Breast Cancer Research and Treatment, 2010, 121, 503-509.	2.5	31
124	Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. Breast Cancer Research and Treatment, 2012, 134, 583-593.	2.5	31
125	Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Research and Treatment, 2005, 94, 279-284.	2.5	30
126	Insights Into the Role of Progesterone Receptors in Breast Cancer. Journal of Clinical Oncology, 2005, 23, 931-932.	1.6	30

#	Article	IF	Citations
127	Growth factors as mediators of estrogen/ antiestrogen action in human breast cancer cells. Cancer Treatment and Research, 1991, 53, 289-304.	0.5	29
128	Secreted growth factors from estrogen receptor-negative human breast cancer do not support growth of estrogen receptor-positive breast cancer in the nude mouse model. Breast Cancer Research and Treatment, 1988, 11, 211-219.	2.5	27
129	Proportional hazards and recursive partitioning and amalgamation analyses of the southwest oncology group node-positive adjuvant CMFVP breast cancer data base: a pilot study. Breast Cancer Research and Treatment, 1992, 22, 273-284.	2.5	27
130	Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. Breast Cancer Research and Treatment, 2010, 124, 433-439.	2.5	26
131	Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Research and Treatment, 2016, 158, 441-454.	2.5	26
132	Myeloperoxidase Genotypes and Enhanced Efficacy of Chemotherapy for Early-Stage Breast Cancer in SWOG-8897. Journal of Clinical Oncology, 2009, 27, 4973-4979.	1.6	24
133	The Oncogenic STP Axis Promotes Triple-Negative Breast Cancer via Degradation of the REST Tumor Suppressor. Cell Reports, 2014, 9, 1318-1332.	6.4	24
134	Aromatase inhibitors: Future directions. Journal of Steroid Biochemistry and Molecular Biology, 2005, 95, 183-187.	2.5	23
135	Adjuvant therapy in node-negative breast cancer. Breast Cancer Research and Treatment, 1989, 13, 97-115.	2.5	22
136	GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. Breast Cancer Research and Treatment, 2018, 170, 279-292.	2.5	22
137	Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer. Breast Cancer Research and Treatment, 2010, 123, 651-660.	2.5	21
138	Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis. BMC Cancer, 2019, 19, 220.	2.6	19
139	Endocrine therapy testing of human breast cancers in the soft agar clonogenic assay. Breast Cancer Research and Treatment, 1985, 6, 229-235.	2.5	18
140	Serum tamoxifen concentrations in the athymic nude mouse after three methods of administration. Cancer Chemotherapy and Pharmacology, 1987, 20, 316-8.	2.3	18
141	Tumor and serum tamoxifen concentrations in the athymic nude mouse. Cancer Chemotherapy and Pharmacology, 1989, 23, 68-70.	2.3	15
142	Dominant-Negative Nuclear Receptor Corepressor Relieves Transcriptional Inhibition of Retinoic Acid Receptor but Does Not Alter the Agonist/Antagonist Activities of the Tamoxifen-Bound Estrogen Receptor. Molecular Endocrinology, 2003, 17, 1543-1554.	3.7	14
143	Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27. Clinical Breast Cancer, 2018, 18, 78-87.	2.4	13
144	Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition. Molecular Cancer Therapeutics, 2018, 17, 921-930.	4.1	11

#	Article	IF	Citations
145	Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia. Breast Cancer Research and Treatment, 2019, 177, 427-435.	2.5	11
146	Management of hormone receptorâ€"positive, human epidermal growth factor 2â€"negative metastatic breast cancer. Breast Cancer Research and Treatment, 2021, 190, 189-201.	2.5	10
147	HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials.. Journal of Clinical Oncology, 2018, 36, 509-509.	1.6	10
148	ICI 182,780 (Faslodexâ„¢). Cancer, 2000, 89, 817-825.	4.1	9
149	Biomarker analysis of PALLET: A neoadjuvant trial of letrozole (L) Â± palbociclib (P).. Journal of Clinical Oncology, 2019, 37, 570-570.	1.6	9
150	Aromatase Inhibitor Adverse Effects: Are We Sweeping Them Under the Rug?. Journal of Clinical Oncology, 2014, 32, 3779-3779.	1.6	8
151	A neoadjuvant, randomized, open-label phase II trial of afatinib (A) versus trastuzumab (T) versus lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC).. Journal of Clinical Oncology, 2012, 30, 606-606.	1.6	8
152	Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2â^' Breast Cancer. Clinical Cancer Research, 2022, 28, 163-174.	7.0	8
153	Molecular Mechanisms of Endocrine Resistance. Cancer Drug Discovery and Development, 2019, , 265-307.	0.4	5
154	Megestrol acetate in breast cancer â€" A panel discussion. Breast Cancer Research and Treatment, 1989, 14, 33-38.	2.5	4
155	Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study. Clinical Breast Cancer, 2019, 19, 225-235.e2.	2.4	4
156	Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models. Npj Breast Cancer, 2021, 7, 63.	5.2	4
157	A multiparameter classifier to predict response to lapatinib plus trastuzumab (LT) without chemotherapy in HER2+ breast cancer (BC).. Journal of Clinical Oncology, 2020, 38, 1011-1011.	1.6	4
158	Pain control in breast cancer. Breast Cancer Research and Treatment, 1989, 13, 5-15.	2.5	3
159	BRCA1 in Clinical Breast Cancer. Breast Disease, 1998, 10, 77-88.	0.8	3
160	bclâ€2 and apoptosis in lymph node positive breast carcinoma. Cancer, 1998, 82, 1296-1302.	4.1	3
161	PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial.. Journal of Clinical Oncology, 2018, 36, 1025-1025.	1.6	3
162	Abstract PD3-09:HER2 L755Smutation is acquired upon resistance to lapatinib and neratinib and confers cross-resistance to tucatinib and trastuzumab in HER2-positive breast cancer cell models. , 2021, , .		2

#	Article	IF	Citations
163	Scalp Cooling Alopecia Prevention trial (SCALP) for patients with early stage breast cancer.. Journal of Clinical Oncology, 2017, 35, 10088-10088.	1.6	2
164	8 Steroid Receptors in Relation to Response. , 1988, 1, 84-99.		1
165	Evaluation of tumor immune infiltrate as a determinant of response to neo-adjuvant lapatinib and trastuzumab (LT) in HER2-positive (+) breast cancer (BC).. Journal of Clinical Oncology, 2016, 34, 608-608.	1.6	1
166	Abstract PD8-06: Acquired resistance to tucatinib is associated with EGFR amplification in HER2+ breast cancer (BC) models and can be overcome by a more complete blockade of HER receptor layer. Cancer Research, 2022, 82, PD8-06-PD8-06.	0.9	1
167	Abstract P4-01-01: Resistance to next generation tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer (BC): Role of <i>HER</i> and <i>PIK3CA</i> mutations and development of new treatment strategies and study models. Cancer Research, 2022, 82, P4-01-01-P4-01-01.	0.9	1
168	A randomized, multicenter, placebo-controlled, phase III study to evaluate the efficacy and safety of HER2/neu peptide GLSI-100 (GP2 + GM-CSF) in patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01.. Journal of Clinical Oncology, 2022, 40, TPS1110-TPS1110.	1.6	1
169	Adjuvant therapy for stage II, estrogen receptor negative breast cancer. Breast Cancer Research and Treatment, 1981, 1, 131-134.	2.5	0
170	Abstract PS5-29: Insights into the molecular underpinnings of the mevalonate pathway-YAP/TAZ-driven anti-HER2 therapy resistance in HER2+ breast cancer (BC). , 2021, , .		0
171	Genetic assessment of hereditary breast and ovarian cancer in the Harris Health System: A five-year, single-center experience.. Journal of Clinical Oncology, 2021, 39, 10587-10587.	1.6	0
172	Change in management based on actionable mutations in metastatic breast cancer in an ethnically diverse cohort: Single institution experience.. Journal of Clinical Oncology, 2021, 39, e13067-e13067.	1.6	0
173	A prospective, randomized, multicenter, double-blinded, placebo-controlled phase III trial of the HER2/neu peptide GP2 + GM-CSF versus bacteriostatic saline/WFI placebo as adjuvant therapy after any trastuzumab-based therapy in HER2-positive women with operable breast cancer.. Journal of Clinical Oncology, 2021, 39, TPS604-TPS604.	1.6	0
174	Abstract 2992: Proteogenomic characterization of triple-negative breast cancer patient-derived xenografts reveals molecular correlates of differential chemotherapy response and potential therapeutic targets to overcome resistance. , 2021, , .		0
175	Scalp cooling alopecia prevention trial (SCALP).. Journal of Clinical Oncology, 2014, 32, TPS9660-TPS9660.	1.6	0
176	Scalp cooling alopecia prevention trial (SCALP) for patients with early stage breast cancer.. Journal of Clinical Oncology, 2016, 34, TPS10144-TPS10144.	1.6	0
177	Vitamin D and aromatase inhibitor-induced arthralgia: Analysis of Canadian cancer trial group MA.27 data.. Journal of Clinical Oncology, 2016, 34, 10020-10020.	1.6	0
178	DE-ESCALATING TREATMENT FOR HER2-POSITIVE EARLY BREAST CANCER. Transactions of the American Clinical and Climatological Association, 2020, 131, 119-126.	0.5	0
179	Abstract PD1-05: Targeting the FRA1-dependent transcriptional nexus in high FOXA1-driven endocrine-resistant and metastatic breast cancer. Cancer Research, 2022, 82, PD1-05-PD1-05.	0.9	0
180	Abstract OT1-18-07: A randomized, multicenter, placebo-controlled, phase III study to evaluate the efficacy and safety of HER2/neu peptide GLSI-100 (GP2 + GM-CSF) in patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy. Cancer Research, 2022, 82, OT1-18-07-OT1-18-07.	0.9	0

#	Article	IF	Citations
181	Abstract P5-07-01: Proteogenomic analysis of differential chemotherapy responses in patient-derived xenografts of triple-negative breast cancer. Cancer Research, 2022, 82, P5-07-01-P5-07-01.	0.9	0
182	Abstract P2-09-09: Genetic assessment of hereditary breast and ovarian cancer in the Smith Clinic: A 10-year, single center experience. Cancer Research, 2022, 82, P2-09-09-P2-09-09.	0.9	0
183	Abstract CT232: A randomized, multicenter, placebo-controlled, phase III study to evaluate the efficacy and safety of HER2/neu peptide GLSI-100 (GP2 + GM-CSF) in patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01. Cancer Research, 2022, 82, CT232-CT232.	0.9	0
184	Effect of mevalonate pathway inhibitors on outcomes of patients (pts) with HER2-positive early breast cancer (BC) in the ALTTO trial.. Journal of Clinical Oncology, 2022, 40, 522-522.	1.6	0